賽升藥業(300485.SZ)擬斥5000萬元參設醫藥中小發展基金
格隆匯8月15日丨賽升藥業(300485.SZ)公佈，鑑於北京經濟技術開發區作為北京全國科技創新中心建設“三城一區”中的“一區”主陣地，設立亦莊醫藥中小企業發展基金，有利於在生物醫藥領域引導產業聚集、帶動區域發展。發揮產業服務、產業培育的作用，保證生物醫藥成果轉化落地，孵化中小企業，促進開發區生物醫藥園區企業的產業鏈合作互補。同時，增強北京市經濟技術開發區醫藥領域企業核心競爭能力，優化行業資源配置，推進北京市經濟技術開發區生物醫藥產業整合升級以及生物醫藥企業做優做強。
公司擬使用不超過5000萬元自有資金與北京亦莊投資控股有限公司、北京屹唐賽盈基金管理有限公司共同發起成立北京亦莊醫藥中小企業發展投資中心(有限合夥)(以工商管理部門最終核准登記的名稱為準，以下簡稱“醫藥中小發展基金”)。
醫藥中小發展基金由北京亦莊投資控股有限公司、賽升藥業、屹唐賽盈、北京市中小企業創業投資引導基金擬共同出資和募集設立，計劃總規模2億元人民幣。
醫藥中小發展基金擬主要投資於生物醫藥領域，包括生物技術創新藥、高端化學創新藥、生物醫學材料、醫學診斷試劑及設備、特色中成藥等。同時通過整合公司相關產業、上下游企業，加強上市公司對上述領域的研發和市場控制能力，做優做強。該基金採用有限合夥方式運作，計劃基金存續期為8年(前4年為投資期，後4年為退出期)。
公司此次擬參與設立醫藥中小發展基金旨在藉助專業的投資團隊、投資渠道及強大的資源整合能力，充分結合公司的行業經驗、技術判斷與資源優勢，積極尋求生物醫藥產業優秀企業的投資機會，依據公司發展戰略路徑進行戰略投資項目選擇，有效實現公司戰略擴張計劃及資本增值。
此次合作是公司戰略擴張創新模式的再次探索，有助於公司加速佈局覆蓋大健康產業相關領域，加強核心能力建設促進戰略目標的持續推進與快速發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
